Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Biotechnology
Russian drugmaker Biocad is expanding into the therapeutic area of psoriatic drugs, through the launch of production of its new treatment Efleira (netakimab), according to recent statements by the company, reports The Pharma Letter’s local correspondent. 29 July 2019
Pharmaceutical
Just a year or two ago, shareholders at Spanish dermatology specialist Almirall would have embraced half-year financial results like those presented on Monday, but perhaps expectations have risen alongside sales and earnings. 29 July 2019
Biotechnology
Last year, Denmark-headquartered dermatology specialist LEO Pharma increased the size of its investment in R&D to 18%, compared to the 15% of the previous year. 25 July 2019
Biotechnology
British medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has published a positive Final Appraisal Document (FAD), confirming that Skyrizi (risankizumab) is recommended for the treatment of severe psoriasis in adult patients who have failed conventional systemic therapies. 15 July 2019
Pharmaceutical
US pharma giant Pfizer saw its shares rise more than 1% to $43.77 by close of trading on Monday, after it announced top-line results from a Phase IV study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged three months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema. 2 July 2019
Biotechnology
National Health Service patients in the UK will be the first to gain access in Europe to new skin cancer treatment, Libtayo (cemiplimab), through the Cancer Drugs Fund (CDF), it was revealed today, just a day after the drug won conditional regulatory approval from the European Commission. 2 July 2019
Biotechnology
Sun Pharmaceutical Industries has entered into a licensing agreement with a subsidiary of China Medical System Holdings (CMS) for the development and commercialization of tildrakizumab in Greater China. 1 July 2019
Pharmaceutical
On the M&A front last week, the spotlight was on AbbVie’s proposed $63 billion acquisition of troubled drugmaker Allergan, which gained a great deal of attention, as well as Bristol-Myers divestment of psoriasis drug Otezla in order to proceed with its $74 billion bid for Celegene. Research news included Conatus Pharmaceuticals’ setback with the failure of its non-alcoholic steatohepatitis (NASH) candidate CTS-2099, adding to a litany of disappointments in the search of a treatment for this liver disease. Meantime, Gilead Sciences entered into a couple of licensing deals linking up with Carna Biosciences on next-generation immuno-oncology compounds and with Nurix on cancer and other diseases. 30 June 2019
Pharmaceutical
Almirall has picked up a handy loan worth 120 million euros ($136 million) from the European Investment Bank (EIB). 26 June 2019
Pharmaceutical
Of all the talk about the pros and cons of AbbVie’s $63 billion takeover of Allergan – which was announced on Tuesday – perhaps the most compelling came from Stat News. 26 June 2019
Biotechnology
Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe from USA-based Dermira. 25 June 2019
Pharmaceutical
Expectations that AbbVie would soon spend its significant cash pile have been answered by the US pharma company in a big way, with the announcement that it is to acquire Ireland-incorporated drugmaker Allergan for $63 million. 25 June 2019
Biotechnology
Positive Phase II results on the first topical gene therapy sent a US biotech company’s share price up by 27% in Monday morning’s trading. 24 June 2019
Biotechnology
Bristol-Myers Squibb has announced that, to help proceed its $74 billion acquisition of biotech major Celgene, it would sell one of the latter’s top-selling drugs, Otezla (apremilast). 24 June 2019
Biotechnology
Today, at the 24th World Congress of Dermatology (WCD) taking place in Milan, Italy, US biotech firm Incyte (Nasdaq: INCY) presented 24-week data from its Phase II study evaluating ruxolitinib cream as a treatment for adult patients with vitiligo. 15 June 2019
Biotechnology
Indian drugmaker Sun Pharmaceutical Industries’ Ilumya is impressing in a new indication beyond its current plaque psoriasis label, new data presented at EULAR has shown. 14 June 2019
Biotechnology
US pharma major Eli Lilly presented results at EULAR on Friday from the Phase IIIb/IV SPIRIT trial comparing its drug Taltz (ixekizumab) with AbbVie’s Humira (adalimumab) in active psoriatic arthritis (PsA). 13 June 2019
Biotechnology
Novartis has boasted that Cosentyx (secukinumab) has become the first drug to show efficacy in all key manifestations of psoriatic arthritis (PsA). 12 June 2019
Biotechnology
US drugmaker AbbVie’s hopes that Skyrizi (risankizumab) will help to replace revenues lost when Humira (adalimumab) competition starts to bite, have been boosted further. 11 June 2019
Biotechnology
US biotech major Celgene (Nasdaq: CELG) presented data from the first full readout of the APPRECIATE real-world evidence (RWE) study at the World Congress of Dermatology (WCD) in Milan. APPRECIATE is the largest RWE study of Otezla (apremilast), involving 480 patients across six European countries. 11 June 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze